Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer

Journal of the National Cancer Institute

Volumn 90, Issue 11, 1998, Pages 814-823

  Colditz, Graham A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; ENVIRONMENTAL FACTOR; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT;

EID: 0032478958     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.11.814     Document Type: Review

References (99)

1. Steinberg KK, Thaker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer [published erratum appears in JAMA 1991;266:1362]. JAMA 1991;265:1985-90.
2. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5:415-21.
3. Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
4. Armstrong BK. Estrogen therapy after the menopause - boon or bane? Med J Aust 1988;148:213-4.
5. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
6. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956;9:927-34.
7. Paffenbarger RS Jr, Kampert JB, Chang HG. Characteristics that predict risk of breast cancer before and after the menopause. Am J Epidemiol 1980;112:258-68.
8. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 1990;46:796-800.
9. Rosner B, Colditz GA. Nurses' Health Study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 1996;88:359-64.
10. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983;303:767-70.
11. Henderson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science 1991;254:1131-8.
12. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994;139:819-35.
13. Janerich DT, Hoff MB. Evidence for a crossover in breast cancer risk factors. Am J Epidemiol 1982;116:737-42.
14. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995;4:567-71.
15. World Bank. Social indicators of development 1993. Baltimore (MD): The Johns Hopkins University Press, 1993.
16. Colditz GA. A biomathematical model of breast cancer incidence: the contribution of reproductive factors to variation in breast cancer incidence. In: Fortner JG, Sharp PA, editors. General Motors Cancer Research Foundation. Accomplishments in cancer research 1996. Philadelphia: Lippincott-Raven, 1997:116-21.
17. Key TJ, Pike MC. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24:29-43.
18. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87: 1297-302.
19. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, et al. Re: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status [letter]. J Natl Cancer Inst 1997;89: 396-8.
20. Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer 1989;44:23-30.
21. Adami HO, Rimsten A, Stenkvist B, Vegelius J. Influence of height, weight and obesity on risk of breast cancer in an unselected Swedish population. Br J Cancer 1977;36:787-92.
22. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-11.
23. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eav less fat. The Kowa Women's Heanth Study. Cancer 1995;76:275-83.
24. Coaves RJ, Clark WS. Eley JW, Greenberg RS, Huguley CM Jr, Brown RL. Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 1990;82:1684-92.
25. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-15.
26. Sowers MR, Wallace RB, Lemke JH. Correlates of mid-radius bone density among postmenopausal women: a community study. Am J Clin Nutr 1985; 41;1045-53.
27. Cauley JA, Gutai JP, Kuller LH, Scott J, Nevitt MC. Black-white differences in serum sex hormones and bone mineral density. Am J Epidemiol 1994;139:1035-46.
28. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276:1404-8.
29. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Elllison RC, Dorgan JF, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997;336:611-7.
30. Olsson H, Hagglund G. Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures. Am J Epidemiol 1992;136:422-7.
31. Persson I, Adami HO, McLaughlin JK, Naessen T, Fraumeni JF Jr. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control 1994;5:523-8.
32. Oza AM, Boyd NF. Mammographie parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15:196-208.
33. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographie densities and breast cancer risk: results from the Canadian National Breast Screening Trial. J Natl Cancer Inst 1995;87:670-5.
34. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographie breast parenchymal density. J Clin Oncol 1997;15:3201-7.
35. Marugg RC, van der Mooren MJ, Hendriks JH, Rolland R, Ruijs SH. Mammographie changes in postmenopausal women on hormonal replacement therapy. Eur Radiol 1997;7:749-55.
36. Kaufman Z, Garstin WI, Hayes R, Michell MJ, Baum M. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 1991;43:389-92.
37. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
38. Hankinson SE, Manson JE, London SJ, Willett WC, Speizer FE. Laboratory reproducibility of endogenous hormone levels in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1994;3:51-6.
39. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
40. Cauley J, Lucas F, Kuller L, Stone K, Cummings SR. Is bone mineral density a biological marker of a woman's cumulative exposure to estrogen? Presented at a meeting of the American Epidemiological Society, Rochester, MN, March 13 and 14, 1997.
41. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997;76:401-5.
42. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
43. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
44. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al. Relation of prediagnostic serum estrogen and androgen levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-9.
45. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125:791-9.
46. Garland CF, Freidlander NJ, Barrett-Connor E, Khaw KT. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992;135:1220-30.
47. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997; 8:922-8.
48. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, et al. Relation of serum levels of testosterone and dehyroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030-8.
49. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
50. Erlik Y, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982;59:403-7.
51. Hagen C, Christiansen C, Christensen MS, Transbol I. Climacteric symptoms, fat mass, and plasma concentrations of LH, FSH, Prl, oestradiol-17 beta and androstenedione in the early post-menopausal period. Acta Endocrinol (Copenh) 1982;101:87-92.
52. Mango D, Scirpa P, Battaglia F, Bini E, Plasma androstenedione and oestrone levels in the climacteric syndrome. Maturitas 1984;5:245-50.
53. Longcope C, Crawford S, McKinlay S. Endogenous estrogens: relationship between estrone, estradiol, non-protein bound estradiol, and hot flashes and lipids. Menopause 1996;3:77-84.
54. Johannes CB, Crawford SL, Posner JG, McKinlay SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 1994;140:439-52.
55. Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993;118: 657-65.
56. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
57. Langenberg P, Kjerulff KH, Stolley PD. Hormone replacement and menopausal symptoms following hysterectomy. Am J Epidemiol 1997;146: 870-80.
58. Barrett-Connor E. Postmenopausal estrogen and the risk of breast cancer. Ann Epidemiol 1994;4:177-80.
59. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes Control 1995;6:416-24.
60. Isaacs AJ, Britton AR, McPherson K. Why do women doctors in the UK take hormone replacement therapy? J Epidemiol Community Health 1997; 51:373-7.
61. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
62. Blohm PL, Hammond CB. Oral estrogen replacement. In: Adashi EY, Rock JA, Resenwaks Z, editors. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott-Raven, 1996;1797-815.
63. Adashi EY. Transdermal estrogen replacement. In: Adashi EY, Rock JA, Resenwaks Z, editors. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott-Raven, 1996:1783-95.
64. Sillero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and risk of breast cancer: a meta-analysis. Obstet Gynecol 1992;79: 286-94.
65. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
66. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
67. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274: 137-42.
68. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women [published erratum appears in Am J Epidemiol 1996;143:527]. Am J Epidemiol 1995;142:788-95.
69. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50: 7415-21.
70. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
71. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20: 1139-44.
72. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991;48:206-10.
73. Clarke C, Sutherland R. Progestin regulation of cellular proliferation. update 1993. In: Horwitz K, editor. Endocrine reviews. Monograph 1. Endocrine aspects of cancer. Bethesda (MD): Endocr Soc, 1993; 132-5.
74. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically post-menopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174: 93-100.
75. Wren B. Hormonal replacement therapy and breast cancer. Eur Menopause J 1995;2:13-9.
76. Myers JS, Connor RE. Cell proliferation in fibrocystic disease and post-menopause breast ducts measured by thymidine labeling. Cancer 1982;50: 746-51.
77. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
78. Gambrell RD J, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-43.
79. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
80. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo VB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130: 221-8.
81. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992;80:400-4.
82. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7:449-57.
83. Brinton LA. Hormone and risk of cancers of the breast and ovary [editorial]. Cancer Causes Control 1996;7:569-71.
84. Tomatis L, Aitio A, Day NE, Heseltine E, Kaldor J, Miller AB, et al. Cancer: causes, occurrence and control. Lyon: International Agency for Research on Cancer, 1990.
85. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
86. Weed DL, Gorelic LS. The practice of causal inference in cancer epidemiology. Cancer Epidemiol Biomarkers Prev 1996;5:303-11.
87. Weed DL. Causal criteria and Popperian refutation. In: Rothman KJ, editor. Causal inference. Chestnut Hill (MA): Epidemiologic Resources Inc., 1988:15-32.
88. Weed DL. Meta-analysis under the microscope [editorial]. J Natl Cancer Inst 1997;89:904-5.
89. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995; 4:649-54.
90. Committee to Review the NIH Women's Health Initiative. An assessment of the NIH Women's Health Initiative. Washington (DC): National Academy Press, 1993.
91. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995;311:1356-9.
92. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
93. National Center for Health Statistics. Health, United States, 1996-97. Hyattsville (MD): Public Health Service, 1997.
94. Kosary C, Ries L, Miller B, Hankey BF, Harras A, Edwards BK, et al. SEER cancer statistics review, 1973-1992: tables and graphs. Bethesda (MD): National Cancer Institute, 1995.
95. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995;87:265-73.
96. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279: 359-64.
97. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
98. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996;334:884-90.
99. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-75.